Division of Mental Health and Substance Abuse, Diakonhjemmet Hospital, Postboks 23 Vinderen, Oslo, 0319, Norway.
Department of Psychology, Norwegian University of Science and Technology, Trondheim, NO-7491, Norway.
Health Qual Life Outcomes. 2023 Apr 15;21(1):35. doi: 10.1186/s12955-023-02116-y.
The EQ-5D is a commonly used generic measure of health but evidence on its responsiveness to change in mental health is limited. This study aimed to explore the responsiveness of the five-level version of the instrument, the EQ-5D-5 L, in patients receiving treatment for depression and anxiety.
Patient data (N = 416) were collected at baseline and at end of treatment in an observational study in a Norwegian outpatient clinic. Patients were adults of working age (18-69 years) and received protocol-based metacognitive or cognitive therapy for depression or anxiety according to diagnosis. Responsiveness in the EQ-5D was compared to change in the Beck Depression Inventory-II (BDI-II) and the Beck Anxiety Inventory (BAI). Effect sizes (Cohen's d), Standardised response mean (SRM), and Pearson's correlation were calculated. Patients were classified as "Recovered", "Improved", or "Unchanged" during treatment using the BDI-II and the BAI. ROC analyses determined whether the EQ-5D could correctly classify patient outcomes.
Effect sizes were large for the BAI, the BDI-II, the EQ-5D value and the EQ VAS, ranging from d = 1.07 to d = 1.84. SRM were also large (0.93-1.67). Pearson's correlation showed strong agreement between change scores of the EQ-5D value and the BDI-II (r -0.54) and moderate between the EQ-5D value and the BAI (r -0.43). The EQ-5D consistently identified "Recovered" patients versus "Improved" or "Unchanged" in the ROC analyses with AUROC ranging from 0.72 to 0.84.
The EQ-5D showed good agreement with self-reported symptom change in depression and anxiety, and correctly identified recovered patients. These findings indicate that the EQ-5D may be appropriately responsive to change in patients with depression and anxiety disorders, although replication in other clinical samples is needed.
EQ-5D 是一种常用的通用健康衡量标准,但关于其在心理健康方面变化的反应性的证据有限。本研究旨在探讨该工具的五维版本,即 EQ-5D-5L,在接受抑郁和焦虑治疗的患者中的反应性。
在挪威一家门诊诊所的观察性研究中,在基线和治疗结束时收集了患者数据(N=416)。患者为 18-69 岁的成年工作年龄人群,根据诊断接受基于认知疗法或元认知疗法的协议治疗。EQ-5D 的反应性与贝克抑郁量表第二版(BDI-II)和贝克焦虑量表(BAI)的变化进行了比较。计算了效应大小(Cohen's d)、标准化反应均值(SRM)和 Pearson 相关系数。使用 BDI-II 和 BAI,将治疗期间的患者分为“康复”、“改善”或“无变化”。ROC 分析确定 EQ-5D 是否能够正确分类患者的结果。
BAI、BDI-II、EQ-5D 值和 EQ VAS 的效应大小较大,范围从 d=1.07 到 d=1.84。SRM 也较大(0.93-1.67)。Pearson 相关系数显示 EQ-5D 值与 BDI-II 的变化评分之间具有很强的一致性(r=-0.54),与 BAI 的变化评分之间具有中度一致性(r=-0.43)。在 ROC 分析中,EQ-5D 始终能够将“康复”患者与“改善”或“无变化”患者区分开来,AUROC 范围从 0.72 到 0.84。
EQ-5D 与抑郁和焦虑的自我报告症状变化具有良好的一致性,并且能够正确识别康复患者。这些发现表明,EQ-5D 可能适当响应抑郁和焦虑障碍患者的变化,尽管需要在其他临床样本中进行复制。